Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CBP501 + Cisplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CBP501||CBP-501|CBP 501||CHK1 Inhibitor 15||CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275, PMID: 29088764).|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 7||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04953962||Phase II||CBP501 + Cisplatin + Nivolumab Cisplatin + Nivolumab CBP501 + Cisplatin||Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer||Active, not recruiting||USA||0|